Literature DB >> 28275049

Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells.

Un-Ho Jin1, Yating Cheng1, Beiyan Zhou1, Stephen Safe2.   

Abstract

Structurally related pentacyclic triterpenoids methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate [bardoxolone-methyl (Bar-Me)] and methyl 2-trifluoromethyl-3,11-dioxoolean-1,12-dien-30-oate (CF3DODA-Me) contain 2-cyano-1-en-3-one and 2-trifluoromethyl-1-en-3-one moieties, respectively, in their A-rings and differ in the position of their en-one structures in ring C. Only Bar-Me forms a Michael addition adduct with glutathione (GSH) and inhibits IKKβ phosphorylation. These differences may be due to steric hindrance by the 11-keto group in CF3DODA-Me, which prevents Michael addition by the conjugated en-one in the A-ring. In contrast, both Bar-Me and CF3DODA-Me induce reactive oxygen species in HL-60 and Jurkat leukemia cells, inhibit cell growth, induce apoptosis and differentiation, and decrease expression of specificity proteins (Sp) 1, 3, and 4, and cMyc, and these effects are significantly attenuated after cotreatment with the antioxidant GSH. In contrast to solid tumor-derived cells, cMyc and Sp transcriptions are regulated independently and cMyc plays a more predominant role than Sp transcription factors in regulating HL-60 or Jurkat cell proliferation and differentiation compared with that observed in cells derived from solid tumors.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28275049      PMCID: PMC5399643          DOI: 10.1124/mol.116.106245

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  47 in total

1.  Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.

Authors:  Marina Konopleva; Twee Tsao; Peter Ruvolo; Irina Stiouf; Zeev Estrov; Clinton E Leysath; Shourong Zhao; David Harris; Shirong Chang; C Ellen Jackson; Mark Munsell; Nanjoo Suh; Gordon Gribble; Tadashi Honda; W Stratford May; Michael B Sporn; Michael Andreeff
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

2.  The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.

Authors:  M Konopleva; R Contractor; S M Kurinna; W Chen; M Andreeff; P P Ruvolo
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

3.  The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore.

Authors:  Paul S Brookes; Kimberly Morse; Denise Ray; Andrew Tompkins; Sara M Young; Shannon Hilchey; Suhail Salim; Marina Konopleva; Michael Andreeff; Richard Phipps; Steven H Bernstein
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

4.  Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.

Authors:  Marina Konopleva; Elena Elstner; Teresa J McQueen; Twee Tsao; Andrey Sudarikov; Wei Hu; Wendy D Schober; Rui-Yu Wang; David Chism; Steven M Kornblau; Anas Younes; Steven J Collins; H Phillip Koeffler; Michael Andreeff
Journal:  Mol Cancer Ther       Date:  2004-10       Impact factor: 6.261

5.  Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives.

Authors:  Gayathri Chadalapaka; Indira Jutooru; Alan McAlees; Tom Stefanac; Stephen Safe
Journal:  Bioorg Med Chem Lett       Date:  2008-03-14       Impact factor: 2.823

6.  The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance.

Authors:  Takashi Ikeda; Michael Sporn; Tadashi Honda; Gordon W Gribble; Donald Kufe
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

Review 7.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

8.  Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.

Authors:  Erik Hedrick; Syng-Ook Lee; Ravi Doddapaneni; Mandip Singh; Stephen Safe
Journal:  Endocr Relat Cancer       Date:  2015-07-30       Impact factor: 5.678

9.  Targeting oxidative stress in embryonal rhabdomyosarcoma.

Authors:  Xiang Chen; Elizabeth Stewart; Anang A Shelat; Chunxu Qu; Armita Bahrami; Mark Hatley; Gang Wu; Cori Bradley; Justina McEvoy; Alberto Pappo; Sheri Spunt; Marcus B Valentine; Virginia Valentine; Fred Krafcik; Walter H Lang; Monika Wierdl; Lyudmila Tsurkan; Viktor Tolleman; Sara M Federico; Chris Morton; Charles Lu; Li Ding; John Easton; Michael Rusch; Panduka Nagahawatte; Jianmin Wang; Matthew Parker; Lei Wei; Erin Hedlund; David Finkelstein; Michael Edmonson; Sheila Shurtleff; Kristy Boggs; Heather Mulder; Donald Yergeau; Steve Skapek; Douglas S Hawkins; Nilsa Ramirez; Philip M Potter; John A Sandoval; Andrew M Davidoff; Elaine R Mardis; Richard K Wilson; Jinghui Zhang; James R Downing; Michael A Dyer
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

10.  Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cells.

Authors:  Erik Hedrick; Yating Cheng; Un-Ho Jin; Kyounghyun Kim; Stephen Safe
Journal:  Oncotarget       Date:  2016-04-19
View more
  6 in total

1.  In Vitro Biotransformation of the Nrf2 Activator Bardoxolone: Formation of an Epoxide Metabolite That Undergoes Two Novel Glutathione-Mediated Metabolic Pathways: Epoxide Reduction and Oxidative Elimination of Nitrile Moiety.

Authors:  Amin M Kamel; Stephen Bowlin; Ban Anwar; Holly Reichard; Joe Argus; Ian A Blair
Journal:  Chem Res Toxicol       Date:  2019-10-25       Impact factor: 3.739

2.  CXCL11-CXCR3 Axis Mediates Tumor Lymphatic Cross Talk and Inflammation-Induced Tumor, Promoting Pathways in Head and Neck Cancers.

Authors:  Subhashree Kumaravel; Sumeet Singh; Sukanya Roy; Lavanya Venkatasamy; Tori K White; Samiran Sinha; Shannon S Glaser; Stephen H Safe; Sanjukta Chakraborty
Journal:  Am J Pathol       Date:  2020-02-05       Impact factor: 4.307

3.  Reactive Oxygen Species (ROS)-Inducing Triterpenoid Inhibits Rhabdomyosarcoma Cell and Tumor Growth through Targeting Sp Transcription Factors.

Authors:  Ravi Kasiappan; Indira Jutooru; Kumaravel Mohankumar; Keshav Karki; Alexandra Lacey; Stephen Safe
Journal:  Mol Cancer Res       Date:  2019-01-04       Impact factor: 5.852

4.  Location, Orientation and Aggregation of Bardoxolone-ME, CDDO-ME, in a Complex Phospholipid Bilayer Membrane.

Authors:  Vicente Galiano; José A Encinar; José Villalaín
Journal:  J Membr Biol       Date:  2020-01-21       Impact factor: 1.843

Review 5.  Triterpenoids as Reactive Oxygen Species Modulators of Cell Fate.

Authors:  Taotao Ling; Lucinda Boyd; Fatima Rivas
Journal:  Chem Res Toxicol       Date:  2022-03-21       Impact factor: 3.973

6.  Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells.

Authors:  Namrata Khurana; Partha K Chandra; Hogyoung Kim; Asim B Abdel-Mageed; Debasis Mondal; Suresh C Sikka
Journal:  Antioxidants (Basel)       Date:  2020-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.